FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2653-2655 June 21, 2007 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Heparin-induced thrombocytopenia is a transient disorder in which thrombocytopenia appears about 1 week after exposure to heparin.¹ Often there is also arterial or venous thrombosis, including adrenal necrosis due to adrenal-vein thrombosis. Heparin-induced thrombocytopenia is caused by platelet-activating antibodies against platelet factor 4 (PF4)–heparin complexes. Its frequency is reduced by a factor of about 10 with low-molecular-weight heparin as compared with unfractionated heparin. The risk of heparin-induced thrombocytopenia is believed to be even lower — perhaps negligible — with fondaparinux (Arixtra),² a factor Xa inhibitor modeled after a critical heparin pentasaccharide sequence. To our knowledge, a causal . . . [Full Text of this Article]

This article has been cited by other articles:

• Blackmer, A. B., Oertel, M. D, Valgus, J. M (2009). Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues. The Annals of Pharmacotherapy 43: 1636-1646 [Abstract] [Full Text]  
• Elalamy, I., Le Gal, G., Nachit-Ouinekh, F., Lafuma, A., Emery, C., Le-Fur, C., Chapuis, F. (2009). Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France. CLIN APPL THROMB HEMOST 15: 428-434 [Abstract]  
• Ortel, T. L. (2009). Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. ASH Education Book 2009: 225-232 [Abstract] [Full Text]  
• Kelton, J. G., Warkentin, T. E. (2008). Heparin-induced thrombocytopenia: a historical perspective. Blood 112: 2607-2616 [Full Text]  
• Authors/Task Force Members, , Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galie, N., Pruszczyk, P., Bengel, F., Brady, A. J.B., Ferreira, D., Janssens, U., Klepetko, W., Mayer, E., Remy-Jardin, M., Bassand, J.-P., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Zamorano, J.-L., Andreotti, F., Ascherman, M., Athanassopoulos, G., De Sutter, J., Fitzmaurice, D., Forster, T., Heras, M., Jondeau, G., Kjeldsen, K., Knuuti, J., Lang, I., Lenzen, M., Lopez-Sendon, J., Nihoyannopoulos, P., Perez Isla, L., Schwehr, U., Torraca, L., Vachiery, J.-L. (2008). Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29: 2276-2315 [Full Text]  
• Phillips, K. W., Dobesh, P. P., Haines, S. T. (2008). Considerations in using anticoagulant therapy in special patient populations. Am J Health Syst Pharm 65: S13-S21 [Abstract] [Full Text]  
• Warkentin, T. E., Greinacher, A., Koster, A., Lincoff, A. M. (2008). Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 340S-380S [Abstract] [Full Text]  
• Batke-Hastings, S., Carman, T. L (2008). Sublingual administration of warfarin: a novel form of delivery. Vasc Med 13: 123-126 [Abstract]  
• Brown, E. N., Herrington, J. D. (2008). Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment. Journal of Pharmacy Practice 21: 126-137 [Abstract]  
• Turpie, A. G.G. (2008). Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit. Eur Heart J Suppl 10: C1-C7 [Abstract] [Full Text]  
• Musharrafieh, U. M., Bizri, A. R. N., Nassar, N. T., Rahi, A. C., Shoukair, A. M., Doudakian, R. M., Hamadeh, G. N. (2008). Health care workers' exposure to blood-borne pathogens in Lebanon. Occup Med (Lond) 58: 94-98 [Abstract] [Full Text]  
• Fareed, J., Bick, R. L., Rao, G., Goldhaber, S. Z., Sasahara, A., Messmore, H. L., Happensteadt, D. A., Nicolaides, A. (2008). The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products. CLIN APPL THROMB HEMOST 14: 5-7  
• Young, G. (2008). New Anticoagulants in Children. ASH Education Book 2008: 245-250 [Abstract] [Full Text]